News from LabCorp Holdings (LH) include a range of developments and financial details. The key highlights include the introduction of a new Alzheimer's blood test which could change the possibility of investment in the company. There has been a significant uptake of LH shares by retirement and independent funds like the Illinois Municipal Retirement Fund, Madison Asset Management, Raleigh Capital Management, and Allianz Asset Management. Labcorp is facing a biotech funding crunch, and has cut growth outlooks as investors express concerns, impacting the stock in Q4. However, other key metrics project a positive image, such as the company’s net margin surge to 6.2%, reinforcing a bullish earnings turnaround narrative. LabCorp continues its innovative push in the Oncology sector with dividends and MRD expansion. The company holds regular dividends of $0.72 per stock. LabCorp's CEO sold a significant number of shares, which to some can create uncertainties. However, LabCorp is considered by brokerages as a moderate buy, indicating a positive minute movement for its stock.
Laboratory Corporation of America Holdings LH News Analytics from Tue, 11 Mar 2025 07:00:00 GMT to Sat, 14 Feb 2026 17:12:04 GMT -
Rating 6
- Innovation 4
- Information 9
- Rumor 8
